Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer
- Sponsor
- Tampere University Hospital
- Study ID
- NCT07594327
- Status
- Enrolling By Invitation
Conditions
- Cervical Cancers
- Endometrial Cancer
- Gynecologic Cancers
- Vaginal Cancers
- Vulvar Cancers
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Pelvic exenteration is an exceptionally extensive and very rare surgical procedure, most commonly used in the treatment of locally recurrent cervical cancer among gynecological malignancies. It is typically performed with curative intent when no other treatment options remain feasible. The aim of this study is to examine the quality of life and sexuality of patients who have undergone pelvic exenteration. This observational cross-sectional study utilizes internationally validated questionnaires assessing quality of life and sexual function: EORTC QLQ-C30, EORTC QLQ-CX24, and PISQ-12. The findings of this study will provide important guidance for the selection and planning of pelvic exenteration. Improved understanding of postoperative quality of life will support patient selection and enable more comprehensive and individualized patient counseling.
Key Dates
- Start date
- May 31, 2026
- Status verified
- May 2026
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 21 participants (estimated)
Primary Outcome Measure
Self-reporterd quality of life measured by EORTC QLQ-C30 questionnaire [ Time Frame: Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration ]
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood SamplesRecruiting · Stanford University · Stanford, California
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama